R&D channel feed – Endpoints News

R&D channel feed

Aurinia bounces back, shares soar on positive data for lupus drug

9 years ago

The top 10 orphan drugs in the late-stage pipeline

9 years ago

Thumped by the FDA, Accera’s attempt to do a serious Alzheimer’s PhIII ends with a flop

9 years ago

Cempra slashes staff while shares tank (again) after a new series of setbacks for lead antibiotic

9 years ago

Kite scores a landmark win with promising 6-month lymphoma data for lead CAR-T

9 years ago

Genentech doubles down on its PhIII Alzheimer’s campaign for crenezumab

9 years ago

Gates-backed Affinivax grabs $10M upfront and a major league partner for a groundbreaking attempt to beat Pfizer’s superstar vaccine

9 years ago

Gerngross’ Adimab hands over RSV antibodies to Arsanis, a biotech he co-founded in Vienna

9 years ago

Exelixis, Bristol-Myers mount pivotal study of Cabo/Opdivo combo for frontline kidney cancer

9 years ago

La Jolla’s lead drug hits the primary in PhIII, igniting shares as execs hustle to the FDA

9 years ago

Struggling Ohr shutters lab after halting enrollment for PhIII wet AMD study

9 years ago

In the wake of a disaster, Cempra shares shoot up on a promising PhIII antibiotic matchup

9 years ago

Merck tees up US/European applications for letermovir after detailing PhIII antiviral success

9 years ago

Roche confirms patient death in ACE910 PhIII hemophilia trial, spurring new questions about top blockbuster hopeful

9 years ago

Incyte turns to Penn for a collaboration on next-gen cancer combos

9 years ago

Genmab outlines a megablockbuster future for itself and J&J as Darzalex gains market traction

9 years ago

Cyclacel unveils a flop in leukemia 2 years after a call on futility, but still won’t give up

9 years ago

Argos’ PhIII for its personalized cancer vaccine implodes during an interim analysis

9 years ago

Agenus’ lead cancer vaccine flops, investigators read last rites over glioblastoma PhII

9 years ago

Cidara shares tank after lead antifungal program flops in PhII

9 years ago

Trevena says its PhIII pain drug program is a winner, but shares crater

9 years ago

In the hunt for a megablockbuster, Celgene plans FDA filing in wake of PhIII win for ozanimod in MS

9 years ago

AstraZeneca throws down the gauntlet with a PhIII victory in head-to-head PARP war with Tesaro

9 years ago

ArQule’s lead drug tivantinib flops again in PhIII liver cancer study

9 years ago

First page Previous page 305 306 307308309 310 311 Next page Last page